News

Public · Published

HIMS May See Heightened 'Gyrations' As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows

Jefferies lowered its price target for Hims & Hers Health to $24 from $31 and kept a Hold rating, citing uncertainty around weight-loss drug demand. It said changing prescription trends could make subscriptions more volatile and lead to sharper swings in the company's stock.

Published:

Updated:

What happened

Jefferies lowered its price target for Hims & Hers Health to $24 from $31 and kept a Hold rating, citing uncertainty around weight-loss drug demand. It said changing prescription trends could make subscriptions more volatile and lead to sharper swings in the company’s stock.

Confirmed

Global impact / market context

Subscriber numbers fell by about 100,000 from the prior quarter even as they remained 13% above a year earlier. If changing demand for weight-loss prescriptions makes subscriptions less predictable, Hims & Hers may need to adjust advertising spending, affecting customer growth, revenue, and investor confidence.

Analyst inference

The article presents reduced advertising spending as the main reason for the quarterly subscriber decline, while analysts also link lower marketing spending to the weaker quarter. This creates uncertainty about whether customer growth reflects softer demand, lower promotion, or both, complicating expectations for revenue.

Analyst inference

What to watch

  1. Watch upcoming subscriber updates for whether the roughly 100,000 sequential decline reverses, stabilizes, or continues as the company and analysts describe changing weight-loss prescription trends. Analyst inference
  2. Track advertising and marketing spending disclosures alongside subscriber growth; higher promotion could help attract customers but would raise costs and may not ensure sustained subscriptions. Analyst inference
  3. Compare future results with Jefferies’ $24 target and Hold rating, and Needham’s $32 target and Buy rating, while noting that both analysts cited lower marketing spending. Confirmed

Evidence